VAP(R) Cholesterol Test Helps Researchers Identify Treatment Effects Of Combination Therapy
Using the VAP Cholesterol Test from Atherotech, Inc., investigators led by Michel Farnier M.D., of Point Medical, Rond Point de la Nation, Dijon, France, have reported beneficial changes in lipoprotein subclasses and LDL particle size using combination therapy. The information could be helpful to physicians because of the known association between abnormal lipoprotein subfractions and increased cardiovascular risk in patients with mixed hyperlipidemia.
More: continued here
Filed under: Cholesterol on November 21st, 2008